期刊
JOURNAL OF PALLIATIVE MEDICINE
卷 14, 期 10, 页码 1167-1172出版社
MARY ANN LIEBERT, INC
DOI: 10.1089/jpm.2011.0109
关键词
-
资金
- Agency for Healthcare Quality and Research
- National Cancer Institute
- Nation Institute of Nursing Research (National Institutes of Health [NIH])
- National Institute of Aging (NIH)
- Robert Wood Johnson Foundation
- Pfizer
- Lilly
- Bristol Myers Squibb
- Helsinn
- Amgen
- Kanglaite
- Abbott Laboratories
Background: Dyspnea is a common symptom experienced by many patients with chronic, life-threatening, and/or life-limiting illnesses. Although it can be defined and measured in several ways, dyspnea is best described directly by patients through regular assessment, as its burdens exert a strong influence on the patient's experience throughout the trajectory of serious illness. Its significance is amplified due to its impact on family and caregivers. Discussion: Anatomic and physiologic changes associated with dyspnea, and cognitive perceptions related to patients and the underlying disease, provide insights into how to shape interventions targeting this oppressive symptom. Additionally, as described in the concept of total dyspnea, the complex etiology and manifestation of this symptom require multidisciplinary treatment plans that focus on psychological, social, and spiritual distress as well as physical components. Several validated assessment tools are available for clinical and research use, and choice of method should be tailored to the individual patient, disease, and care setting in the context of patient-centered care. Conclusion: This article, the first in a two-part series, reviews the identification and assessment of dyspnea, the burden it entails, and the underlying respiratory and nonrespiratory etiologies that may cause or exacerbate it.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据